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ABSTRACT
Systematic reviews suggest that homeopathy has a greater effect than placebo, however, the mechanisms of
its action are unknown. The clinical effects of homeopathy could be attributed to the specific effects of the rem-
edy and/or to the contextual effects of the consultation process; these factors have not been critically evaluated.
We have developed a model that attempt to separate the consultation effects from the specific effects because
of the remedy. We propose to investigate this design in a chronic condition, rheumatoid arthritis, for which pre-
vious research has evaluated both classical and complex homeopathic interventions. The following protocol de-
scribes the study design. The aims of this exploratory trial are to assess the feasibility of the study design, iden-
tify effect sizes of the consultation, the complex treatment, and the individualized remedy, as well as possibly
efficacy, for the two types of homeopathic treatment and the homeopathic consultation. Data collection will
take place in 2004.
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INTRODUCTION
Homeopathy is contentious. Surveys confirm that pa-tients use and continue to use homeopathy (Eisenberg
et al., 1998), and feel satisfied with their treatment (Richard-
son, 2001). A meta-analysis (Linde et al., 1997) and three
systematic reviews (Cucherat et al., 2000; Hill and Doyon,
1990; Kleijnen et al., 1991) suggest that in “good” quality
trials, homeopathy has a significantly greater effect than
placebo (Hill and Doyon, 1990; Kleijnen et al., 1991; Linde
et al., 1997) although the strength of the effect is disputable
(Cucherat et al., 2000) and engenders much debate. How-
ever these positive clinical effects are still largely unex-
plained (Linde et al., 1997) because currently no plausible
mechanism to explain its action exists. In addition, previous
randomized controlled trials show that therapeutic im-
provements are observed in both verum and placebo groups
(Linde et al., 1997). This has raised questions about where
the effects of homeopathy lie: is it the material and chemi-
cal interactions caused by the homeopathic remedy or the
nonspecific (“contextual”) effects of the consultation, or
both?
Contextual factors include those that are not the result of
the active components of the treatment but are inherent
within the treatment “package,” (Di Blasi et al., 2001; Hy-
land, 2003; Moerman and Jonas 2002; Walach, 2003) and
can include a myriad of factors related to the practitioner
(e.g. the practitioners’ manner and attention to their patients,
their expectations, etc.), the patient (expectations of out-
come, attitudes, hope, philosophical belief in treatment,
etc.), and the therapeutic relationship as well as the charac-
teristics of the setting, for example, the credibility of the
treatment. Current trends have shifted toward understanding
those factors such as the therapeutic relationship and patient-
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centered factors (e.g., empathy, empowerment, etc; Di Blasi
et al., 2001) that may mediate the apparent success of the
homeopathic process.
This current study propose a conceptual model to sepa-
rate out and identify the effect sizes of both the specific and
nonspecific aspects of the homeopathic process. We propose
to test this model in the chronic condition rheumatoid arthri-
tis (RA) in which there is both evidence and a rationale to
use both classical and complex homeopathic approaches. A
meta-analysis of three of the four randomized controlled tri-
als (three trials used individualized homeopathy [Andrade
et al., 1991; Fisher and Scott, 2001; Gibson et al., 1980])
and one used complex homeopathy that was reported in the
literature twice (Kohler, 1991; Wiesenauer and Gaus, 1991)
identified an odds ratio of 2.0 in favor of homeopathy al-
though only the study that used complex homeopathy
showed a clear statistically significant result (Kohler, 1991;
Wiesenauer and Gaus, 1991). Therefore, based in the con-
text of this disease, this protocol proposes a conceptual
model to answer the principal question of the study: “Can
the effects of the homeopathic consultation be separated and
measured separately from the homeopathic remedy?”
This will not be a definitive study. The aims of this pro-
tocol will be to assess the feasibility of the study design, to
identify the consultation process and separate it from the
homeopathic remedy, and to identify the following effect
sizes: (1) the placebo effect, with and without the consulta-
tion, (2) the effect of the consultation, (3) the effect of the
individual remedy, (4) the effect of the homeopathic com-
plex, and (5) the difference in effects between complex
homeopathy and individual homeopathy. Other additional
patient centered aims were identified.
MATERIALS AND METHODS
The trial design is a placebo-controlled, randomized dou-
ble-blinded exploratory pilot trial will be conducted at Well-
come Trust Clinical Research Facility, Southampton Gen-
eral Hospital. 
Patients with relatively stable RA disease will be recruited
from teaching hospitals in the southern part of England. In-
clusion criteria will be as follows: between 18–75 years of age,
diagnosed with RA for more than 2 years (based on Ameri-
can College of Rheumatology [ACR] Guidelines; Arnett et al.,
1988); on stable medication for longer than 2 months. Exclu-
sion criteria includes patients with severe comorbidities, those
taking immunosuppressant drugs or biologic disease-modify-
ing antirheumatic drugs (i.e., antitumor-necrosis factor [TNF]);
those classified as functional status class IV in the ACR cri-
teria; use of homeopathy less than 3 months; and pregnancy
or breastfeeding. There will be 20 per arm.
Patients will be randomized into five groups as shown in
Figure 1 to investigate the effects of homeopathy with and
without a consultation. Three of the groups received a con-
sultation (groups 1, 2, and 3) and two groups (groups 4 and
5) will receive no consultation. The consultation group pa-
tients will be randomized to receive either individualized
treatment (group 1), a complex designed for RA (group 2),
or placebo (group 3).
Those subjects allocated to groups 4 and 5 will receive
either the complex or placebo. The study design allowed for
the following comparisons to be investigated:
• The effect of the consultation can be assessed by com-
paring the consultation and nonconsultation groups (i.e.,
group 2 versus group 4), and also from group 3 versus
group 5.
• The effect of the complex treatment can be assessed by
comparing groups 2 versus 3 and, additionally, group 4
versus group 5.
• The effect of the individualized remedy can be assessed
by comparing groups 1 and 3.
• The difference in effect between the individualized treat-
ment and the complex can be determined by comparing
group 1 and group 2.
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FIG. 1. Study design showing randomization scheme. Numbers represent study groups as described in the text.
Treatment
Patients will be allocated to one of the five study arms,
as described in Figure 1. Each patient will be enrolled in the
study for 10 months (i.e., 1 month baseline, 6 months of
treatment, and 3 months of follow-up). After baseline as-
sessment all patients will attend a standardized monthly
clinic visit during the treatment phase where outcome mea-
sures will be recorded by the study nurse. Subjects who are
randomized to consultation will also receive a homeopathic
consultation. The homeopaths, blinded to treatment alloca-
tion, will prescribe from the whole repertoire but remain re-
stricted to a standardized dosing regimes to maintain blind-
ing. Homeopathic prescriptions for each patient who receive
consultations will be faxed to an independent pharmacy
where the appropriate prescription (i.e., a classically pre-
scribed remedy for group 1, a complex for group 2, and a
placebo for group 3) will be sent to the patients. Patients
will complete weekly diaries between clinic visits. Subjects
will be followed up 3 months after the treatment phase.
Strategies to minimize drop-out rates will be used.
Trial medication
The independent pharmacy will send all patients their study
medication after each clinic visit during the treatment phase.
This will include 1 bottle of tablet medication (which will
contain either classical remedy or placebo as appropriate, to
be taken one tablet twice per day) and a bottle of liquid (which
will contain the homeopathic complex or placebo as appro-
priate with a dosing regimen of 20 drops twice per day). The
complex remedy is a commercial preparation (Dreluso, Hes-
sisch Oldendorf, Germany) containing Rhus Tox D4, Bryonia
cretica D4, Stychnos nux vomica D4, Berberis vulgaris D4,
Ledum palustre D4 in a 20-mL solution that has been used
in previous trials (Kohler, 1991; Wiesenauer and Gaus, 1991).
The placebo complex remedy will contain the same as the
verum minus the homeopathic remedies. Individualized reme-
dies will be prescribed according to the consultation from the
whole repertoire and in any appropriate dose but on standard
dosing frequency. The medication can be prepared as pre-
scribed constitutional (i.e., tablets 1 to 3 would be the con-
stitutional remedy prescribed) followed by dummy or acute
remedy (for tablets 4 to end). For subjects who receive
placebo, all tablets will contain placebo.
OUTCOME ASSESSMENT
The primary outcome measures will be: (1) whether the
subjects achieve a 20% improvement (binary variable) 
in global RA symptoms based on the outcome measures
from the Outcome Measures for Arthritis Clinical Trials
(OMERACT; Fries et al., 1980), which include assessment
of joint pain/tenderness, joint swelling, visual analogue scale
(VAS) pain, acute phase reactants, functional status, and pa-
tient and physician global assessment; and (2) weekly VAS
pain scores. There will be a number of secondary outcomes
including individual assessment of OMERACT outcomes,
quality of life assessment, and global assessments. A range
of covariates will be investigated as possible predictors of
treatment outcome (e.g., patient/physician’s expectations,
attitudes about CAM, and for subjects who are allocated to
consultation patient perceived empathy, enablement, and
sense of emotional meaning attributable to the process).
Data analysis
The data will be analyzed on an intention-to-treat basis.
The binary primary outcome variable will be evaluated us-
ing logistic regression analysis, adjusted for baseline and
other confounding factors. The continuous primary outcome
measure will be assessed by repeated measures analysis of
variance (ANOVA). Pair-wise comparisons will be made
between those receiving a homeopathic remedy (complex)
versus placebo in consultation and nonconsultation groups.
RESULTS
Data collection will commence 2004. Part funding has been
secured from the Samueli Institute, Corona del Mar, CA.
CONCLUSION
It is not anticipated that the power of the study will be
adequate to identify small group differences, and the design
is based on the assumption that the effects of case taking,
the remedy and other effects that contribute to the study ef-
fect are additive. However, this study will identify whether
the model proposed to separate the effects of the homeo-
pathic consultation from the remedy is feasible. In addition
this study will provide further evidence for the effect of
homeopathy in rheumatoid arthritis. If it is successful, this
investigative model may have broad relevance to both CAM
and conventional medicine.
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